Expiration date: 07/2025
The composition and form of issue:
1 ml solution contains 0.001 g of thymodepressin and excipients (sodium chloride, water for injection) in ampoules of 1 ml in the pan 5 PCs. complete with ampulnam knife, in a cardboard bundle 1 tray or in vials to 5 ml complete with dropper cap, in a cardboard box 1 vial.
Feature:
Synthetic peptide, consisting of D-amino acid residues of glutamic acid and tryptophan.
Colorless transparent liquid.
Pharmacological action:
It inhibits the reaction of humoral and cellular immunity. On a cellular level reduces the absolute content of peripheral blood lymphocytes (as a helper, and suppressor). Contributes to maintaining the number of stem cells in the peripheral blood in severe autoimmune processes (cytopenia, psoriasis).
Reduces the time of recovery of populations comicyoung (CFU-S?8) and pluripotent (CFU-S?12) of predecessors of hemopoiesis after exposure to cytostatic drugs.
It has no mutagenic and teratogenic properties.
Indications:
Treatment of pathological States which are accompanied with hyperimmune reactions: autoimmune one-, two - and trehrozhkovye cytopenia (primary or secondary), aplastic anemia, protection and preservation of stem cells and prevention of granulocytopenia during chemotherapy with cytostatics, systemic diseases of connective tissue (rheumatoid arthritis), psoriasis.
Contraindications:
Individual intolerance of thymodepressin, uncontrolled hypertension, infectious diseases in acute phase, pregnancy.
Application of pregnancy and breast-feeding:
Contraindicated in pregnancy. With caution during breast-feeding.
Side effects:
Allergic reactions.
Drug interactions:
Information on drug interactions.
Method of application and dose:
V/m, 1-2 ml/day for 7 days. The course may be repeated after a break of 7 days.
Intranasally, 1 ml of 1 times a day for 7 days, followed by breaks of 7 days between courses.
In the process of treatment dose and duration are correct.
Precautions:
The drug should be used under the supervision of a physician with experience of immunosuppressive therapy.
Be wary appoint women during breast-feeding, patients with chronic, latent forms of infectious diseases.
With the introduction of the transient decrease in leukocyte count, which recovered with continued treatment.
